Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
121P - DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution
Presenter: Nnenna Kanu
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Comprehensive multi-omics profiling identifies prognostic and predictive subtypes in renal cell carcinoma
Presenter: Sanha Park
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Copy number from ulcWGS to predict TNBC molecular subtypes in the IBCSG 22-00 trial
Presenter: Andrea Joaquin Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
124P - Targeting neoantigens in chronic lymphocytic leukemia (CLL) for personalized T cell therapy
Presenter: Gurvinder Kaur
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Detection and analysis of medulloblastoma subtype-specific copy number variations from RNA-seq data for improved risk-based subtype classification
Presenter: Ivan Martinez de Estibariz Royuela
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Genomic and transcriptomic profiles define smokers and non-smokers lung squamous cell carcinoma patients
Presenter: Matteo Canale
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Metastatic migrations in lung cancer: Insights from the PEACE autopsy programme
Presenter: Sonya Hessey
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - NGS prescreening program for refractory solid tumors outside standard indications in a public network of cancer centers
Presenter: Paula Sàbat Viltró
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Transcriptomic analysis of patients with metastatic hormone-sensitive prostate cancer to identify genomic signatures involved in the transition from androgen-dependent to androgen-independent phenotype
Presenter: Giovanna Pecoraro
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Benchmarking whole exome sequencing in the German network for personalized medicine
Presenter: Michael Menzel
Session: Cocktail & Poster Display session
Resources:
Abstract